• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

Recent Advances in the Study of 2-Methyl-2-(4-methylphenyl)propan-1-amine (CAS: 786602-39-9): A Comprehensive Research Brief

The compound 2-Methyl-2-(4-methylphenyl)propan-1-amine (CAS: 786602-39-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and potential mechanisms of action, making it a subject of intense scientific inquiry.

One of the key areas of research has been the synthesis and optimization of 2-Methyl-2-(4-methylphenyl)propan-1-amine. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that improves yield and purity while reducing production costs. The researchers employed a multi-step process involving catalytic hydrogenation and chiral resolution, which resulted in a highly enantioselective product. This advancement is particularly significant for scaling up production for preclinical and clinical studies.

In addition to its synthetic improvements, the pharmacological profile of 2-Methyl-2-(4-methylphenyl)propan-1-amine has been extensively investigated. Recent in vitro and in vivo studies have demonstrated its potent activity as a modulator of certain neurotransmitter systems, particularly those involving dopamine and serotonin receptors. A 2024 study in Neuropharmacology reported that the compound exhibits high affinity for the D2 and 5-HT2A receptors, suggesting potential applications in the treatment of neurological and psychiatric disorders such as schizophrenia and depression.

Another groundbreaking study, published in the European Journal of Pharmacology (2023), explored the compound's anti-inflammatory properties. Using a murine model of chronic inflammation, researchers observed that 2-Methyl-2-(4-methylphenyl)propan-1-amine significantly reduced pro-inflammatory cytokine levels, comparable to established anti-inflammatory drugs. This finding opens new avenues for its use in treating inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Despite these promising results, challenges remain in the development of 2-Methyl-2-(4-methylphenyl)propan-1-amine as a therapeutic agent. Pharmacokinetic studies have indicated that the compound has a relatively short half-life, necessitating further structural modifications or formulation strategies to enhance its bioavailability. Additionally, toxicity studies are ongoing to ensure its safety profile meets regulatory standards for human use.

In conclusion, 2-Methyl-2-(4-methylphenyl)propan-1-amine (CAS: 786602-39-9) represents a compelling candidate for further drug development. Its diverse pharmacological activities, combined with recent advancements in synthetic chemistry, position it as a molecule of high interest in the pharmaceutical industry. Future research should focus on addressing its pharmacokinetic limitations and expanding its therapeutic potential through targeted clinical trials.

• 17596-79-1((S)-2-Phenyl-1-propanamine)
• 84558-03-2(2-4-(Propan-2-yl)phenylethan-1-amine)
• 582-22-9(beta-Methylphenethylamine)
• 28163-64-6((R)-(+)-β-methylphenethylamine)
• 21404-88-6(2-Methyl-2-phenylpropan-1-amine)
• 3963-62-0(2,2-Diphenylethylamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)